Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women

Thromb Res. 2004;114(3):155-9. doi: 10.1016/j.thromres.2004.05.012.

Abstract

To explain the pathogenesis of preeclampsia with coagulation induction or a defective fibrinolysis, various hemostatic parameters were studied and different treatment modalities targeting these parameters were evaluated. Considering the role of TAFI in down-regulation of fibrinolysis, in our study we have investigated whether TAFI contributes to impaired fibrinolysis in patient with preeclampsia. Thirty patients with preeclampsia (mean age +/- SD 25.7 +/- 4.53; range 17-36) and 30 normal pregnant women as control group (mean age +/- SD 28 +/- 5.26; range 21-38) were included in our study. TAFI antigen was determined using an ELISA kit for quantitative measurement. The mean TAFI antigen levels were 12.55 +/- 1.88 microg/ml in patients with preeclampsia and 12.29 +/- 3.0 microg/ml in normal pregnant women. A statistically significant difference was not found between TAFI antigen levels of two groups (p > 0.05). In order to clarify the role of TAFI in the pathogenesis of preeclampsia, in addition to plasma TAFI levels, its synthesis, activation and metabolism should also be evaluated.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Biomarkers / blood
  • Carboxypeptidase B2 / blood*
  • Female
  • Humans
  • Pre-Eclampsia / blood*
  • Pre-Eclampsia / diagnosis*
  • Pregnancy / blood*
  • Risk Assessment / methods*
  • Risk Factors

Substances

  • Biomarkers
  • Carboxypeptidase B2